Saltar al contenido
Merck
Todas las fotos(1)

Documentos

58451AST

Supelco

CHIRALPAK® HSA (5 μm) HPLC Columns

L × I.D. 15 cm × 4 mm, HPLC Column

Sinónimos:

High Selectivity Chiral HPLC Column

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52

product name

Chiral HSA HPLC Column, 5 μm particle size, L × I.D. 15 cm × 4 mm

material

stainless steel column

agency

suitable for USP L79

product line

CHIRALPAK®

packaging

pkg of 1 ea

manufacturer/tradename

CHIRALPAK®

parameter

137 bar pressure (2000 psi)
20-30 °C temperature
40 °C max. temp.

technique(s)

HPLC: suitable

L × I.D.

15 cm × 4 mm

matrix

fully porous particle

matrix active group

human serum albumin phase

particle size

5 μm

operating pH

2-8

separation technique

chiral

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

CHIRALPAK HSA, which uses human serum albumin as the chiral selector, is highly selective for acidic racemates, preferably weak and strong acids, zwitterionic and non-protolytic (neutral) compounds. Phosphate buffers (normally 0.01-0.1M, pH 5-7) with addition of organic modifiers are used as mobile phases. Enantioselectivity and retention can be regulated by changing the mobile phase composition. However, the primary use of CHIRALPAK HSA is for fast drug/protein binding studies (1). To calculate the % protein binding, measure the retention time of an unretained compound (t0) and the compound of interest (tr) on the CHIRALPAK HSA column. Then use the capacity factor equation:
k = (tr - t0)/tr
to calculate the % protein binding (P):
P = 100k/(k+1)

Different types of mobile phases can be used. A mobile phase consisting of 6% 2-propanol in 20 mM potassium phosphate buffer, pH 7.0 gives data in good agreement with literature data. The mobile phase conditions should be chosen to suit the drugs to be tested, i.e., for high protein binding drugs a mobile phase with higher eluting strength might be needed in order to reduce retention times.

(1) Goodman, A.; Gilman, A.G. The Pharmacological Basis of Therapeutics, 9th Edition, McGraw-Hill: New York, 1996; pp 1712-1792.

Recommended products

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Legal Information

CHIRALPAK is a registered trademark of Daicel Corp.

Choose from one of the most recent versions:

Certificados de análisis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico